Home・Список акций・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Закрыт

СекторЗдравоохранение

9.27 0.87

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

8.94

Макс.

9.51

Ключевые показатели
By Trading Economics
Доход	-1.1B -722M
Продажи	-250M 156M
P/E Средняя по отрасли	7.603 68.51
Прибыль на акцию	0.14
Рентабельность продаж	-461.478
Сотрудники	435
EBITDA	-966M -700M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+130.21% upside

Дивиденды
By Acuity
Следующий отчет о доходах	2 нояб. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-99M 2.2B
Предыдущая цена открытия	8.4
Предыдущая цена закрытия	9.27

Новостные настроения

By Acuity

34%

66%

112 / 340 Рейтинг в Healthcare

BioCryst Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

6 авг. 2026 г., 22:36 UTC

BioCryst Pharmaceuticals shares are lower in after-market trading, continuing a decline since Thursday's close and positioned below the 20-day moving average.

5 авг. 2026 г., 22:36 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading, despite no specific news identified to explain the movement. They remain below their 20-day moving average.

4 авг. 2026 г., 19:36 UTC

Correlated Moves

BioCryst Pharmaceuticals Inc shares are higher today, supported by gains in the biotechnology sector. The stock remains above its earlier low despite recent trends.

3 авг. 2026 г., 19:56 UTC

BioCryst Pharmaceuticals Inc shares are lower today, continuing a downward trend since Friday. The broader market is seeing gains, contrasting with BioCryst's performance.

31 июл. 2026 г., 22:36 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading. No specific news was identified to explain this movement, reflecting routine performance since Friday's close.

30 июл. 2026 г., 20:09 UTC

BioCryst Pharmaceuticals shares are lower amid broader market volatility following mixed economic signals, including rising jobless claims and disappointing GDP growth.

29 июл. 2026 г., 19:35 UTC

BioCryst Pharmaceuticals Inc shares are lower amid a declining market, with no specific company news identified to explain the movement during today's session.

28 июл. 2026 г., 23:06 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading, continuing an upward trend from Tuesday's close, despite an earlier session pullback.

27 июл. 2026 г., 20:01 UTC

BioCryst Pharmaceuticals Inc shares are trading higher in Monday's session, reflecting notable strength despite remaining near the lower end of their one-month trading range.

24 июл. 2026 г., 21:01 UTC

BioCryst Pharmaceuticals Inc. shares are lower in after-market hours, reflecting broader market trends following a decline in the Nasdaq influenced by negative earnings reports.

22 июл. 2026 г., 21:51 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market trading, continuing a decline amid significant volatility in U.S. markets and lack of specific news.

21 июл. 2026 г., 17:46 UTC

BioCryst Pharmaceuticals Inc shares are higher today, continuing an upward trend since Monday. The stock remains below its 20-day moving average.

20 июл. 2026 г., 19:16 UTC

Correlated Moves

Shares lower amid decline in Biotechnology sub-sector and SPDR ETF.

Сравнение c конкурентами

Изменение цены

BioCryst Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

130.21% рост

Прогноз на 12 месяцев

Средняя 20.88 USD 130.21%

Максимум 32 USD

Минимум 12 USD

Основано на мнении 8 аналитиков Wall Street, спрогнозировавших целевые цены для BioCryst Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

8 ratings

Покупка

Удержание

Продажа

Основано на мнении 8 аналитиков, присваивавших рейтинги акциям BioCryst Pharmaceuticals Inc – Данные за последние 3 месяца.

Настроения

By Acuity

112 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.